Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.19.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 43,462 $ 48,995
Marketable securities 175,132 129,669
Accrued interest receivable 509 304
Prepaid research and development expenses 7,900 1,670
Other prepaid expenses 768 924
Total current assets 227,771 181,562
Property and equipment, net 2,549 2,905
Operating lease right-of-use asset 219  
Other assets 1,261 2,280
Total assets 231,800 186,747
Current liabilities:    
Accounts payable 1,494 1,973
Accrued research and development expenses 10,819 8,588
Other accrued liabilities 5,045 3,854
Total current liabilities 17,358 14,415
Long-term portion of operating lease liability 1,851  
Other liabilities   1,914
Total liabilities 19,209 16,329
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value: 100,000,000 shares authorized; 68,701,043 and 59,456,493 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively 7 6
Additional paid-in capital 808,866 693,534
Accumulated other comprehensive income (loss) 177 (58)
Accumulated deficit (596,459) (523,064)
Total stockholders’ equity 212,591 170,418
Total liabilities and stockholders’ equity $ 231,800 $ 186,747